Thomas J. Wilson

Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

ImmunoMolecular Therapeutics LLC develops and manufactures immuno-therapeutic drugs for autoimmune diseases. The firm offers oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. The company was founded by Steve Orndorff, Aaron Michels, and Peter Gottlieb in 2015 and is headquartered in Broomfield, CO.

Ebi Life Sciences, Inc. is a private company that specializes in researching and developing life sciences. The company is based in Cambridge, MA.

Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA.

ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN.

Eumentis Therapeutics, Inc. manufactures novel drugs. The American company was founded by Mark A. Tepper and he has been the CEO since incorporation.